These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 350557)

  • 41. Effects of probucol on the high density lipoprotein system in hypercholesterolaemic patients.
    Franceschini G; Calabresi L; Chiesa G; Vaccarino V; Sirtori M; Sirtori CR
    Pharmacol Res; 1989; 21(1):113-4. PubMed ID: 2726655
    [No Abstract]   [Full Text] [Related]  

  • 42. Probucol treatment and thyroid function tests.
    Roach L; Botha A; Joffe BI; Baker SG; Shires R; Seftel HC
    S Afr Med J; 1980 Nov; 58(21):833. PubMed ID: 7444683
    [No Abstract]   [Full Text] [Related]  

  • 43. Safety and efficacy of probucol during one year of administration.
    Nash DT
    J Clin Pharmacol; 1974; 14(8):470-5. PubMed ID: 4605082
    [No Abstract]   [Full Text] [Related]  

  • 44. [Effect of probucol on blood lipids].
    Santos Rde O; Moriguchi Y
    Arq Bras Cardiol; 1982 Jul; 39(1):59-61. PubMed ID: 6762872
    [No Abstract]   [Full Text] [Related]  

  • 45. [New derivatives of clofibrate and probucol. Preliminary study of their hypolipemic activity].
    de Meglio P; Ravenna F; Manzardo S; Gentili P; Riva M
    Farmaco Sci; 1985 Nov; 40(11):833-44. PubMed ID: 4085644
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diet and probucol in lowering cholesterol concentrations. Additive effects on plasma cholesterol concentrations in patients with familial type ii hyperlipoproteinemia.
    LeLorier J; DuBreuil-Quidoz S; Lussier-Cacan S; Huang YS; Davignon J
    Arch Intern Med; 1977 Oct; 137(10):1429-34. PubMed ID: 335998
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term oral administration of probucol (4,4'-(isopropylidenedithio) bis(2,6-di-t-butylphenol)) (DH-581) in the management of hypercholesterolemia.
    Harris RS; Gilmore HR; Bricker LA; Kiem IM; Rubin E
    J Am Geriatr Soc; 1974 Apr; 22(4):167-75. PubMed ID: 4594122
    [No Abstract]   [Full Text] [Related]  

  • 48. Clinical experience with probucol with special emphasis on mode of action and long-term treatment.
    Miettinen TA; Huttunen JK; Kuusi T; Kumlin T; Mattila S; Naukkarinen V; Strandberg T
    Artery; 1982; 10(1):35-43. PubMed ID: 7092574
    [No Abstract]   [Full Text] [Related]  

  • 49. [Probuscol (Lurselle)].
    Nouv Presse Med; 1980 Oct; 9(40):2945-3027. PubMed ID: 7443426
    [No Abstract]   [Full Text] [Related]  

  • 50. Probucol further lowers the serum cholesterol of colestipol-treated patients with hypercholesterolemia.
    Schonfeld G; Witztum J; Basich P
    Artery; 1982; 10(2):99-104. PubMed ID: 7092583
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Probucol versus eptastatin in hypercholesterolaemic diabetics.
    Yoshino G; Kazumi T; Uenoyama R; Inui A; Kasama T; Iwatani I; Iwai M; Yokono K; Otsuki M; Baba S
    Lancet; 1986 Sep; 2(8509):740-1. PubMed ID: 2876200
    [No Abstract]   [Full Text] [Related]  

  • 52. [Effect of probucol on serum cholesterol concentration in primary hyperlipoproteinemia].
    Kawecka-Jaszcz K; Kocemba J; Wasowicz B; Król W
    Kardiol Pol; 1982; 25(5-6):377-82. PubMed ID: 6759746
    [No Abstract]   [Full Text] [Related]  

  • 53. [Evaluation of the effect of probucol on blood lipids].
    Giannini SD; Forti N; Ziliotto EE
    Arq Bras Cardiol; 1981 Feb; 36(2):139-42. PubMed ID: 7325835
    [No Abstract]   [Full Text] [Related]  

  • 54. A little more information about aggravation of probucol-induced HDL-reduction by clofibrate.
    Yokoyama S; Yamamoto A; Kurasawa T
    Atherosclerosis; 1988 Mar; 70(1-2):179-81. PubMed ID: 3355613
    [No Abstract]   [Full Text] [Related]  

  • 55. Treatment of hyperlipoproteinemias with neomycin, probucol and tibric acid.
    Miettinen TA
    Adv Exp Med Biol; 1977; 82():483-8. PubMed ID: 920404
    [No Abstract]   [Full Text] [Related]  

  • 56. Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/placebo: Probucol Quantitative Regression Swedish Trial (PQRST): a status report.
    Walldius G; Carlson LA; Erikson U; Olsson AG; Johansson J; Mölgaard J; Nilsson S; Stenport G; Kaijser L; Lassvik C
    Am J Cardiol; 1988 Jul; 62(3):37B-43B. PubMed ID: 3293415
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discrepancies between the outcome of animal and human studies on the mode of action of probucol.
    Beynen AC
    Atherosclerosis; 1986 Sep; 61(3):249-51. PubMed ID: 3768092
    [No Abstract]   [Full Text] [Related]  

  • 58. Probucol, a new cholesterol lowering drug.
    Nash DT
    J Med; 1975; 6(5-6):305-15. PubMed ID: 768396
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Effects of probucol on plasma cholesterol and triglyceride levels].
    Duarte GM; Lavall M
    Arq Bras Cardiol; 1981 Nov; 37(5):431-7. PubMed ID: 7347193
    [No Abstract]   [Full Text] [Related]  

  • 60. [Probucol].
    Yagyu H
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():631-6. PubMed ID: 11347145
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.